ArticleScientific reports2025
A pharmacovigilance study of thromboembolism events associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors based on FAERS database.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- A Disproportionality Analysis of β-lactam Antibiotic Related Blood and Lymphatic System Disorders Based on the FDA Adverse Event Reporting System Database.Health science reports · 2026Article
- Pharmacological Targeting of Angiogenesis in Head and Neck Cancer: Molecular Mechanisms and Emerging Therapeutic Strategies.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Bibliometric study on hotspots and trends of immunotherapy for kidney cancer from 2014 to 2024.Translational andrology and urology · 2026Article
- Thromboembolic events associated with antiangiogenic monoclonal antibodies: a disproportionality analysis from FDA adverse event reporting system (FAERS) database.Thrombosis journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) represent a class of targeted drugs that have changed the cancer therapy landscape. However, the anti-angiogenic effect of VEGFR-TKIs significantly increase the incidence of cardiovascular adverse events (AEs). In this study, we conducted a comprehensive analysis of VEGFR-TKI-related thromboembolic events (TEEs), using data from the FAERS database between the drug launch and the third quarter of 2023. Disproportionality analysis, including reporting odds ratio, proportional reporting ratio, bayesian confidence propagation neural network, and multi-item gamma poisson shrinker, were used to explore the correlation between VEGFR-TKIs and TEEs. The total number of reported TEEs was 2688, representing 2.98% of all AEs associated with VEGFR-TKIs. A total of 17 and 12 preferred terms of arterial and venous thromboembolic events were observed in 8 VEGFR-TKIs. Lenvatinib, a VEGFR-TKI with low selectivity and high potency, exhibited the strongest TEE signal. A tendency of an increased signal of disproportionate reporting of TEEs was observed in sorafenib, regorafenib, and sunitinib. Indication, gender, age, drug class, concomitant medication and AEs may influence the occurrence of VEGFR-TKI-related TEEs. This study illustrates that TEEs are highly associated with VEGFR-TKIs, emphasizing the importance of screening for the TEE risks during VEGFR-TKI therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.